Diagnostic Test Accuracy Protocol

You have free access to this content

Biomarkers for assessing disease activity in inflammatory bowel disease

  1. Mahmoud Mosli1,2,
  2. Marianne Fahmy3,
  3. Sushil K Garg4,
  4. Sean G Feagan5,
  5. Kenneth A Baker5,
  6. GY Zou5,
  7. John K MacDonald5,
  8. William J Sandborn3,
  9. Nilesh Chande6,*

Editorial Group: Cochrane IBD Group

Published Online: 25 NOV 2013

DOI: 10.1002/14651858.CD010848


How to Cite

Mosli M, Fahmy M, Garg SK, Feagan SG, Baker KA, Zou GY, MacDonald JK, Sandborn WJ, Chande N. Biomarkers for assessing disease activity in inflammatory bowel disease (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010848. DOI: 10.1002/14651858.CD010848.

Author Information

  1. 1

    London Health Sciences Centre, Victoria Hospital, London, Ontario, Canada

  2. 2

    King Abdulaziz University, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

  3. 3

    University of California San Diego, La Jolla, CA, USA

  4. 4

    University of Minnesota, Department of Surgery, Minneapolis, MN, USA

  5. 5

    Robarts Research Institute, Robarts Clinical Trials, London, Ontario, Canada

  6. 6

    London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

*Nilesh Chande, London Health Sciences Centre - Victoria Hospital, Room E1-423A, 800 Commissioners Road East, London, Ontario, N6A 5W9, Canada. nchande2@uwo.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 25 NOV 2013

SEARCH

References

Additional references

Casellas 2001
  • Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. European Journal of Gastroenterology and Hepatology 2001;13(5):567-72.
Cobb 2004
  • Cobb WS, Heniford BT, Sigmon LB, Hasan R, Simms C, Kercher KW, et al. Colonoscopic perforations: incidence, management, and outcomes. American Surgeon 2004;70(9):750-7.
Kallel 2010
  • Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. European Journal of Gastroenterology and Hepatology 2010;22(3):340-5.
Langhorst 2008
  • Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. American Journal of Gastroenterology 2008;103(1):162-9.
    Direct Link:
Lasson 2008
Leeflang 2008
  • Leeflang MM, Moons KG, Reitsma JB, Zwinderman AH. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clinical Chemistry 2008;54(4):729-37.
Lichtenstein 2006
  • Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clinical Gastroenterology and Hepatology 2006;4(5):621-30.
Macaskill 2010
  • Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. The Cochrane Collaboration, 2010.
Manz 2012
  • Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterology 2012;12:5.
Review Manager 5 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Roseth 1999
  • Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1999;34(1):50-4.
Rutter 2001
Sipponen 2008
Tibble 2000
Van Rheenen 2010
Walker 2007
  • Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 2007;44(4):414-22.
Whiting 2011
  • Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
Zou 2008